We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.

Sandbox Reserved 191

From Proteopedia

(Difference between revisions)

Jump to: navigation, search

Revision as of 00:13, 3 April 2014

This Sandbox is Reserved from Feb 02, 2011, through Jul 31, 2011 for use by the Biochemistry II class at the Butler University at Indianapolis, IN USA taught by R. Jeremy Johnson. This reservation includes Sandbox Reserved 191 through Sandbox Reserved 200.

To get started:

Click the edit this page tab at the top. Save the page after each step, then edit it again.
Click the 3D button (when editing, above the wikitext box) to insert a 3D applet Jmol scene window.
show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.

More help: Help:Editing

Introduction

is a small glycoprotein hydrolase found in the lysosome that breaks the thioester bond between cysteine amino acids and ^[1]. It is a homodimer that is composed primarily of alpha helices and beta sheets with a hydrophobic groove that allows the palmitic acid[1] to bind, exposing the thioester bond to the catalytic triad. PPT-1 was first found as an enzyme that removed palmitate from GTPase HRas, but over time it has been discovered that is able to remove palmitate from other proteins as well ^[2]. When PPT-1 is not functioning properly, the lipid modified proteins can build up in the cells and cause infantile neuronal ceroid lipofuscinosis[2]^[3]

Surface view of PPT-1 showing the hydrophobic groove and palmitate

Catalytic Triad

PPT-1's structure creates an external hydrophobic groove that binds the palmitate acid in between carbon 4 and 5. The acid binds in a gauche conformations creating a kink in the acid chain. This bending could suggest that PPT-1 was originally designed to react with unsaturated fatty acid with cis-double bonds. The catalytic is composed of Serine 115, Aspartate 233, and Histidine 289. The Serine is "deprotonated" by the Histidine and attacks the carbonyl carbon of the palmitic acid. The negative charge is pushed onto the oxygen and is possible stabilized by a water molecule. The tetrahedral collapses and kicks the palmatic acid off of the cysteine residue^[2].

PPT-1

Anything in this section will appear adjacent to the 3D structure and will be scrollable.

This is a default text for your page Sandbox Reserved 190

Inhibitors of PPT-1

is a lysosomal enzyme which had a serine lipase consensus sequence; a key characteristic of lysosomal enzymes. Despite having a serine lipase consensus sequence, PPT-1, is not deactivated by phenylmethylsulfonyl fluoride (PMSF), a common serine-modifying reagent. (HDSF) is a serine-modifying reagent that is able to inhibit the actions of PPT1 . Unlike other inhibitors, leading away from the active site of PPT-1. PMSF is unable to fit into this small narrow groove due to steric constraints that relate to the unique structure of the substrate-binding site of PPT1. The sulphur of HDSF will via a sulponylation reaction and thus will inhibit the actions of PPT-1.

Disease Associated With PPT-1

Infantile Neuronal Ceroid Lipofuscinosis (INCL) is a recessively inherited disease that is associated with a decrease in PPT-1 activity due to mutations of the PPT-1 enzyme. Onset of symptoms which include retinal blindness, ataxia, seizures, and cortical atrophy of the brain, begin 1-2 years after birth. Death typically occurs between the ages of 8-11. Several mutations in the 1p32 chromosome have been identified to cause INCL.

Mutations Associated with INCL

Juvenile NCL (JNCL) and Late-infantile NCL (LINCL)are less severe forms of INCL in which onset of symptoms occur much later in life, between the ages of 30-40. The mutations associated with JNCL and LINCL occur away from the active site of PPT-1 resulting in a higher activity of the PPT-1 enzyme. A common mutation associated with JNCL and LINCL involves the mutation of Thr-75.

Common Mutation associated with JNCL and LINCL involve mutations Far Away From Active Site

(Bellizzi J. Widom J. Kemp. Lu J. Das K. Hofmann L. Jon Clardy J. 2000. The crystal structure of palmitoyl protein thioesterase1 and the molecular basis of infantile neuronal ceroid lipofuscinosis. Biochemistry. 97: 4573-4578)

Unfortunately not much is known on how to treat INCL. However, in both JNCL and LINCL activity of PPT-1 has only a 2% activity rate compared to normal PPT-1 activity. This suggests that a small increase in activity of PPT-1 may aid in delaying the symptoms associated with INCL. One way in which to increase the activity of PPT-1 is to use protein chaperons that help refold PPT-1 in the endoplasmic reticulm. Although this is not a cure for INCL, by increasing the activity of PPT-1 the life expectancy for individuals with INCL can be greatly increased.

(Dawson G. Schroeder C. Dawson P. 2010. Palmitoyl:protein thioesterase (PPT1) inhibitors can act as pharmacological chaperones in infantile Batten disease. Biochem and Biophys Research Comm. 395. 66-69.)

References

↑ Wang R, Borazjani A, Matthews AT, Mangum LC, Edelmann MJ, Ross MK. Identification of palmitoyl protein thioesterase 1 in human THP1 monocytes and macrophages and characterization of unique biochemical activities for this enzyme. Biochemistry. 2013 Oct 29;52(43):7559-74. doi: 10.1021/bi401138s. Epub 2013 Oct, 18. PMID:24083319 doi:http://dx.doi.org/10.1021/bi401138s
↑ ^2.0 ^2.1 Bellizzi JJ 3rd, Widom J, Kemp C, Lu JY, Das AK, Hofmann SL, Clardy J. The crystal structure of palmitoyl protein thioesterase 1 and the molecular basis of infantile neuronal ceroid lipofuscinosis. Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4573-8. PMID:10781062 doi:10.1073/pnas.080508097
↑ Simonati A, Tessa A, Bernardina BD, Biancheri R, Veneselli E, Tozzi G, Bonsignore M, Grosso S, Piemonte F, Santorelli FM. Variant late infantile neuronal ceroid lipofuscinosis because of CLN1 mutations. Pediatr Neurol. 2009 Apr;40(4):271-6. doi: 10.1016/j.pediatrneurol.2008.10.018. PMID:19302939 doi:http://dx.doi.org/10.1016/j.pediatrneurol.2008.10.018

External Resources

[1] Wikipedia page on palmitic acid.

[2] Wikipedia page on Infantile neuronal ceroid lipofuscinosis

Retrieved from "http://52.214.119.220/wiki/index.php/Sandbox_Reserved_191"

@@ Line 17: / Line 17: @@
 PPT-1's structure creates an external hydrophobic groove that binds the palmitate acid in between carbon 4 and 5.  The acid binds in a gauche conformations creating a kink in the acid chain.  This bending could suggest that PPT-1 was originally designed to react with unsaturated fatty acid with cis-double bonds.  The catalytic <scene name='43/436866/Triad_all_marked/1'>triad</scene> is composed of Serine 115, Aspartate 233, and Histidine 289. The Serine is "deprotonated" by the Histidine and attacks the carbonyl carbon of the palmitic acid.  The negative charge is pushed onto the oxygen and is possible stabilized by a water molecule.  The tetrahedral collapses and kicks the palmatic acid off of the cysteine residue<ref name="mutations" />.
-==Next Section==
+==PPT-1==
+<StructureSection load='3GRO' size='340' side='right' caption='HDSF Binding' scene=''>
+Anything in this section will appear adjacent to the 3D structure and will be scrollable.
+This is a default text for your page '''Sandbox Reserved 190'''
+==Inhibitors of PPT-1==
+'''<scene name='43/436866/Overall-3-rainbow/1'>PPT-1</scene>''' is a lysosomal enzyme which had a serine lipase consensus sequence; a key characteristic of lysosomal enzymes. Despite having a serine lipase consensus sequence, PPT-1, is not deactivated by phenylmethylsulfonyl fluoride (PMSF), a common serine-modifying reagent. <scene name='58/580839/Hdsf_by_itself/1'>Hexadecylsulfonylfluoride</scene>  (HDSF) is a serine-modifying reagent that is able to inhibit the actions of PPT1 <scene name='58/580839/Basic-hdsf-nosurface/4'>by binding to PPT-1</scene>. Unlike other inhibitors, <scene name='58/580839/Basic-hdsf-surfacelook/2'>HDSF is able to fit in the narrow, hydrophobic groove of PPT-1</scene> leading away from the active site of PPT-1. PMSF is unable to fit into this small narrow groove due to steric constraints that relate to the unique structure of the substrate-binding site of PPT1.  The sulphur of HDSF will <scene name='58/580839/Hdsf_bound_to_Ser-115-best/1'>bind to SER-115 in the active site of PPT-1</scene> via a sulponylation reaction and thus will inhibit the actions of PPT-1.
+==Disease Associated With PPT-1==
+Infantile Neuronal Ceroid Lipofuscinosis (INCL) is a recessively inherited disease that is associated with a decrease in PPT-1 activity due to mutations of the PPT-1 enzyme. Onset of symptoms which include retinal blindness, ataxia, seizures, and cortical atrophy of the brain, begin 1-2 years after birth. Death typically occurs between the ages of 8-11. Several mutations in the ''1p32'' chromosome have been identified to cause INCL.
+[[Image:All_mutations.jpg|100px|right|thumb|Mutations Associated with INCL]]
+Juvenile NCL (JNCL) and Late-infantile NCL (LINCL)are less severe forms of INCL in which onset of symptoms occur much later in life, between the ages of 30-40. The mutations associated with JNCL and LINCL occur away from the active site of PPT-1 resulting in a higher activity of the PPT-1 enzyme. A common mutation associated with JNCL and LINCL involves the mutation of Thr-75.
+[[Image:Thr-_mut.png|200px|right|thumb|Common Mutation associated with JNCL and LINCL involve mutations Far Away From Active Site]]
+(Bellizzi J.  Widom J. Kemp.  Lu J. Das K. Hofmann L. Jon Clardy J. 2000. The crystal structure of palmitoyl protein thioesterase1 and the molecular basis of infantile neuronal ceroid lipofuscinosis. Biochemistry. 97: 4573-4578)
+Unfortunately not much is known on how to treat INCL. However, in both JNCL and LINCL activity of PPT-1 has only a 2% activity rate compared to normal PPT-1 activity. This suggests that a small increase in activity of PPT-1 may aid in delaying the symptoms associated with INCL. One way in which to increase the activity of PPT-1 is to use protein chaperons that help refold PPT-1 in the endoplasmic reticulm.  Although this is not a cure for INCL, by increasing the activity of PPT-1 the life expectancy for individuals with INCL can be greatly increased.
+(Dawson G. Schroeder C. Dawson P. 2010.  Palmitoyl:protein thioesterase (PPT1) inhibitors can act as pharmacological chaperones in infantile Batten disease. Biochem and Biophys Research Comm. 395. 66-69.)

Sandbox Reserved 191

From Proteopedia

Revision as of 00:13, 3 April 2014

Introduction

Catalytic Triad

PPT-1

Inhibitors of PPT-1

Disease Associated With PPT-1

References

External Resources

Views

Personal tools

Navigation

Search

Toolbox